C. Grace Yeh

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Amitesh Roy, S. R. Park, David Cunningham et al. · Annals of Oncology · 2013 · 123 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

Ting‐Chang Chang, H. Shiah, Kun‐Huei Yeh et al. · Cancer Chemotherapy and Pharmacology · 2015 · 98 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

<scp>PEPCOL</scp>: a <scp>GERCOR</scp> randomized phase <scp>II</scp> study of nanoliposomal irinotecan <scp>PEP</scp>02 (<scp>MM</scp>‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Jean‐Baptiste Bachet et al. · Cancer Medicine · 2016 · 49 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

Nai‐Jung Chiang, Tsu-Yi Chao, Ruey‐Kuen Hsieh et al. · BMC Cancer · 2016 · 39 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16